What is it about?
We report a case of a patient that had severe hand-foot syndrome and marked drops in their blood cell counts that did not recover after receiving high-dose cytarabine while concurrently receiving posaconazole for re-induction therapy of their acute myelogenous leukemia.
Featured Image
Why is it important?
This case is unique since it is the first example of a potential drug interaction between cytarabine and posaconazole. Future studies need to be performed to see if posaconazole does influence the pharmacokinetics of cytarabine.
Perspectives
This case calls to action a need to evaluate if posaconazole is a P-gp inhibitor in vivo. Labeling of posaconazole as a P-gp inhibitor does not exist on its package insert and further clinical research needs to be performed to clarify whether this is the case or not.
Dr Saeed K. Alzghari
Gulfstream Diagnostics
Read the Original
This page is a summary of: Severe palmar-plantar erythrodysesthesia and aplasia in an adult undergoing re-induction treatment with high-dose cytarabine for acute myelogenous leukemia: a possible drug interaction between posaconazole and cytarabine, Journal of Oncology Pharmacy Practice, August 2016, SAGE Publications,
DOI: 10.1177/1078155216664204.
You can read the full text:
Contributors
The following have contributed to this page
